Anemia Brytikov

Brighter's anemia (lat. Aneuríða Braytii), or Anemic syndrome with refractory hyperchromic anemia, or Bright's disease, is a rare disease that is characterized by the development of pathological changes in the red bone marrow and a decrease in the number of red blood cells in the blood. The disease is classified as hypochromic anemia. The cause of the development of the pathology is a malignant neoplasm with a locally widespread nature.

This is a serious cancer. Metastases spread to other organs. Pathological cells clog the channels, which disrupts metabolic processes in tissues. Because of this, heart failure develops. A person may experience a stroke or heart attack. In advanced cases, patients suffer from a lack of important vitamins and minerals in the body. This condition is called osteoporosis. Without maintenance therapy once the cancer cells have started, the patient is unlikely to survive. Over a short period of time it will begin to fade away.

The disease got its name in honor of the German physician Theodor Schwartz, who described the characteristic manifestations of this form of red bone marrow cancer in his scientific work published in 1844. However, the very development of the pathology, clinical picture, complications and treatment were described by the Swiss physician Karl von Bayer within a separate nosological unit back in 1760. Today, the original original name of the disease is considered more relevant - Bayers anemia, Braunsy Anderson Morris & Tillis syndrome.

According to world statistics, Bright's disease leads to premature death in about 58% of cases (the mortality rate varies between 48-73%). The number of living patients with this pathology is slightly more than 22